Business
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 -- BERKELEY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutic
About this update from Caribou Biosciences, Inc.
[{"type":"image","alt":"Caribou Biosciences, Inc.","displaySize":"","headline":null,"caption":"Caribou Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1HwoXChQuqEwEC6gGN.VhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1HwoXChQuqEwEC6gGN.VhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74}},"lazy":false},{"type":"text","content":"-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL --","length":91,"tagName":"p"},{"type":"text","content":"-- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 --","length":96,"tagName":"p"},{"type":"text","content":"-- CaMMouflage phase 1 trial evaluating CB-011 continues to enroll r/r MM patients, dose escalation and expansion clinical data updates expected in 2026 --","length":155,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter of 2026 and provided a business update.","length":261,"tagName":"p"},{"type":"text","content":"“We are pleased to have aligned with the FDA on the pivotal ANTLER-3 trial design for vispa-cel,” said Rachel Haurwitz, PhD, president and CEO of Caribou. “Vispa-cel continues to demonstrate a differentiated profile as an off-the-shelf CAR-T cell therapy with a well-tolerated safety profile and robust response rates resulting in long-term durable outcomes in high-risk patients. Our pivotal trial will compare vispa-cel to standard-of-care regimens that lack curative intent yet are often the only options available to the 75% of second-line large B cell lymphoma patients who do not receive autologous CAR-T cell therapy. We look forward to reporting longer follow up on the phase 1 data for vispa-cel at an upcoming medical conference this year as well as sharing longer follow up on d...